A Phase 3 Study of VSA001 in Chinese Adults With Familial Chylomicronemia Syndrome
Status:
Not yet recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blinded, placebo controlled, two periods phase 3 clinical study.
The primary objective of the study is to evaluate the efficacy and safety of VSA001 injection
in Chinese adults with familial chylomicronemia syndrome (FCS). A total of approximately 30
participants will be enrolled in the study.